Manufacturer of Controlled Substances; Notice of Registration; Patheon Pharmaceuticals, Inc., 39340-39341 [2013-15563]
Download as PDF
<![CDATA[
39340
Federal Register / Vol. 78, No. 126 / Monday, July 1, 2013 / Notices
Drug
Schedule
Cocaine (9041) .............................
Codeine (9050) .............................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Diphenoxylate (9170) ...................
Ecgonine (9180) ...........................
Ethylmorphine (9190) ...................
Hydrocodone (9193) .....................
Levorphanol (9220) ......................
Meperidine (9230) ........................
Methadone (9250) ........................
Morphine (9300) ...........................
Thebaine (9333) ...........................
Opium, powdered (9639) .............
Levo-alphacetylmethadol (9648) ..
Oxymorphone (9652) ...................
Fentanyl (9801) ............................
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
Boehringer Ingelheim Chemicals, Inc.,
2820 N. Normandy Drive, Petersburg,
Virginia 23805–9372, made application
by renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the following
basic classes of controlled substances:
Amphetamine
(1100) II
Drug Schedule
Methylphenidate (1724) ................
Methadone (9250) ........................
Methadone Intermediate (9254) ...
Tapentadol (9780) ........................
The company plans to import the
listed controlled substances for sale to
research facilities for drug testing and
analysis.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a),
and determined that the registration of
SA INTL GMBH C/O., Sigma Aldrich
Co. LLC., to import the basic classes of
controlled substances is consistent with
the public interest, and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971, at this time. DEA
has investigated SA INTL GMBH C/O.,
Sigma Aldrich Co. LLC., to ensure that
the company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic classes of controlled
substances listed.
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for sale to its customers for formulation
into finished pharmaceuticals. In
reference to Methadone Intermediate
(9254) the company plans to produce
Methadone HCL active pharmaceutical
ingredients (APIs) for sale to its
customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR § 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than August 30, 2013.
Dated: June 18, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–15604 Filed 6–28–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Dated: June 18, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Drug Enforcement Administration
[FR Doc. 2013–15576 Filed 6–28–13; 8:45 am]
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on May 21, 2013,
Chemtos, LLC., 14101 W. Highway 290,
Building 2000B, Austin, Texas 78737–
9331, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
Manufacturer of Controlled
Substances; Notice of Application;
Chemtos, LLC.
BILLING CODE 4410–09–P
mstockstill on DSK4VPTVN1PROD with NOTICES
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application;
Boehringer Ingelheim Chemicals, Inc.
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on May 31, 2013,
VerDate Mar<15>2010
22:39 Jun 28, 2013
Jkt 229001
Drug
Schedule
Amphetamine (1100) ....................
PO 00000
Frm 00090
Fmt 4703
Sfmt 4703
II
Drug
Methamphetamine (1105) ............
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
Nabilone (7379) ............................
Phenylacetone (8501) ..................
Cocaine (9041) .............................
Codeine (9050) .............................
Etorphine HCL (9059) ..................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Ecgonine (9180) ...........................
Ethylmorphine (9190) ...................
Hydrocodone (9193) .....................
Levomethorphan (9210) ...............
Levorphanol (9220) ......................
Isomethadone (9226) ...................
Meperidine (9230) ........................
Meperidine-intermediate-A (9232)
Meperidine-intermediate-B (9233)
Meperidine-intermediate-C (9234)
Methadone (9250) ........................
Methadone intermediate (9254) ...
Morphine (9300) ...........................
Thebaine (9333) ...........................
Dihydroetorphine (9334) ...............
Levo-alphacetylmethadol (9648) ..
Oxymorphone (9652) ...................
Racemethorphan (9732) ..............
Racemorphan (9733) ...................
Schedule
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
small quantities of the listed controlled
substances in bulk for distribution to its
customers for use as reference
standards.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than August 30, 2013.
Dated: June 18, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–15572 Filed 6–28–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration;
Patheon Pharmaceuticals, Inc.
By Notice dated March 20, 2013, and
published in the Federal Register on
March 28, 2013, 78 FR 19016, Patheon
E:\FR\FM\01JYN1.SGM
01JYN1
Federal Register / Vol. 78, No. 126 / Monday, July 1, 2013 / Notices
Pharmaceutical, Inc., 2110 E. Galbraith
Road, Cincinnati, Ohio 45237, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Gamma Hydroxybutyric Acid (2010), a
basic class of controlled substance listed
in schedule I.
The company plans to manufacture
the listed controlled substance for
clinical trials and distribution to its
customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Patheon Pharmaceuticals, Inc., to
manufacture the listed basic class of
controlled substance is consistent with
the public interest at this time. DEA has
investigated Patheon Pharmaceuticals,
Inc., to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the above named company is
granted registration as a bulk
manufacturer of the basic class of
controlled substance listed.
Dated: June 18, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–15563 Filed 6–28–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Federal Bureau of Investigation
[OMB Number 1110–NEW]
Agency Information Collection
Activities: Proposed Collection,
Comments Requested: Notice of
Collection of Information Relative to
Customer Service Satisfaction
mstockstill on DSK4VPTVN1PROD with NOTICES
ACTION:
30-day Notice.
The Department of Justice, Federal
Bureau of Investigation (FBI), National
Center for the Analysis of Violent Crime
(NCAVC), will be submitting the
following information collection request
to the Office of Management and Budget
(OMB) for review and clearance in
accordance with established review
procedures of the Paperwork Reduction
Act of 1995. The proposed information
collection is published to obtain
comments from the public and affected
VerDate Mar<15>2010
21:38 Jun 28, 2013
Jkt 229001
agencies. This proposed information
collection was previously published in
the Federal Register Volume 78,
Number 72, page 22332, on April 15,
2013, allowing for a 60 day comment
period.
The purpose of this notice is to allow
for an additional 30 days for public
comment until July 31, 2013. This
process is conducted in accordance with
5 CFR 1320.10.
ADDRESSES: All comments, suggestions,
or questions regarding additional
information, to include obtaining a copy
of the proposed information collection
instrument with instructions, should be
directed to Yvonne Muirhead, Federal
Bureau of Investigation, NCAVC,
Critical Incident Response Group, FBI
Academy, 1 Range Road, Quantico,
Virginia, 22135.
SUPPLEMENTARY INFORMATION: Written
comments and suggestions from the
public and affected agencies concerning
the proposed collection of information
are encouraged. Comments should
address one or more of the following
four points:
(1) Whether the proposed collection
of information is necessary for the
proper performance of the functions of
the agency, including whether the
information will have practical utility;
(2) Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
(3) Enhance the quality, utility, and
clarity of the information to be
collected; and
(4) Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques of
other forms of information technology,
e.g., permitting electronic submission of
responses.
Overview of this information
collection:
(1) Type of information collection:
Customer satisfaction ratings regarding
the quality and value of the FBI’s
NCAVC services.
(2) The title of the form/collection:
FBI–NCAVC Satisfaction Survey.
(3) There is no agency form number
applicable to this survey.
(4) The survey will be distributed to
state, local and tribal law enforcement
agencies to which the NCAVC has
provided investigative assistance. The
survey is being proposed as a means to
assess the effectiveness and efficiency
with which the NCAVC serves these
agencies in the execution of their
PO 00000
Frm 00091
Fmt 4703
Sfmt 4703
39341
missions. The survey will query
respondents as to the agencies’
satisfaction with NCAVC services, and
concrete achievements which were
furthered via NCAVC services.
(5) Time burden anticipated with this
collection: It is estimated that 100
respondents per calendar year will be
contacted to complete a survey
consisting of 11 questions. An
approximate non-response rate of 50%
is anticipated. It is estimated that a
burden of approximately three to five
minutes, or .05 to .08 hours, will be cast
upon each respondent to complete the
survey, with a total estimate of five to
8.3 hours in a calendar year for all
respondents combined, if all
respondents complete a survey. If the
expected non-response rate of 50%
holds true, then the combined burden
estimate drops to approximately 2.5 to
4.2 hours per calendar year. The
NCAVC estimates little to no variability
within this time estimate based upon on
individualized data retrieval systems,
availability of requested data, and other
variables, because this survey is
intended to assess customer satisfaction
rather than generate empirical data.
(6) Methodology: The survey will be
distributed and collected electronically,
via electronic mail communication.
Contact: If additional information is
required contact: Jerri Murray,
Department Clearance Officer, Policy
and Planning Staff, Justice Management
Division, United States Department of
Justice, Two Constitution Square, 145 N
Street NE., Room 1407B, Washington,
DC 20530.
Dated: June 25, 2013.
Jerri Murray,
Department Clearance Officer for PRA,
United States Department of Justice.
[FR Doc. 2013–15566 Filed 6–28–13; 8:45 am]
BILLING CODE 4410–02–P
NATIONAL AERONAUTICS AND
SPACE ADMINISTRATION
[Notice: 13–070]
NASA Advisory Council; Science
Committee; Planetary Science
Subcommittee; Meeting.
National Aeronautics and
Space Administration.
ACTION: Notice of meeting.
AGENCY:
In accordance with the
Federal Advisory Committee Act, as
amended, the National Aeronautics and
Space Administration (NASA)
announces a meeting of the Planetary
Science Subcommittee of the NASA
Advisory Council (NAC). This
SUMMARY:
E:\FR\FM\01JYN1.SGM
01JYN1
]]>Agencies
[Federal Register Volume 78, Number 126 (Monday, July 1, 2013)]
[Notices]
[Pages 39340-39341]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-15563]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration;
Patheon Pharmaceuticals, Inc.
By Notice dated March 20, 2013, and published in the Federal
Register on March 28, 2013, 78 FR 19016, Patheon
[[Page 39341]]
Pharmaceutical, Inc., 2110 E. Galbraith Road, Cincinnati, Ohio 45237,
made application by renewal to the Drug Enforcement Administration
(DEA) to be registered as a bulk manufacturer of Gamma Hydroxybutyric
Acid (2010), a basic class of controlled substance listed in schedule
I.
The company plans to manufacture the listed controlled substance
for clinical trials and distribution to its customers.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Patheon Pharmaceuticals, Inc., to manufacture the listed basic class of
controlled substance is consistent with the public interest at this
time. DEA has investigated Patheon Pharmaceuticals, Inc., to ensure
that the company's registration is consistent with the public interest.
The investigation has included inspection and testing of the company's
physical security systems, verification of the company's compliance
with state and local laws, and a review of the company's background and
history.
Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21
CFR 1301.33, the above named company is granted registration as a bulk
manufacturer of the basic class of controlled substance listed.
Dated: June 18, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2013-15563 Filed 6-28-13; 8:45 am]
BILLING CODE 4410-09-P?>
